Abstract
In a study of 11 adult patients with acute nonlymphocytic leukemia (ANLL), infusion therapy with high-dose VP-16 and intermediate-dose cytosine arabinoside was administered. Response was assessed with reference to bone marrow aspirations performed on days 1; 12, 13, or 14; and 21 of treatment. All 7 of the patients with ANLL in relapse achieved marrow hypoplasia, and 3 of them achieved complete response. LFTs were elevated in most patients but no evidence of hepatocellular necrosis was observed. It is concluded that the value of VP-16 in ANLL may have been underestimated in the past because of inadequate dosing.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 265-266 |
| Number of pages | 2 |
| Journal | Cancer Chemotherapy and Pharmacology |
| Volume | 20 |
| Issue number | 3 |
| DOIs | |
| State | Published - Sep 1987 |
ASJC Scopus subject areas
- Pharmacology
- Oncology
- Cancer Research
Fingerprint Dive into the research topics of 'High-dose VP-16 with intermediate-dose cytosine arabinoside in the treatment of relapsed acute nonlymphocytic leukemia'. Together they form a unique fingerprint.
Cite this
Chan, H. Y., Meyers, F. J., & Lewis, J. P. (1987). High-dose VP-16 with intermediate-dose cytosine arabinoside in the treatment of relapsed acute nonlymphocytic leukemia. Cancer Chemotherapy and Pharmacology, 20(3), 265-266. https://doi.org/10.1007/BF00570500